COMPANY PROFILE

MediCrops

Explore full profile

Health-tech firm specializing in medical cannabis distribution and digital patient care via telemedicine

Freienbach, SwitzerlandFounded 2019Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About MediCrops

MediCrops AG is a health-tech company specializing in the distribution and advancement of medical cannabis therapies, with a strong focus on digital innovation and telemedicine. Operating in both Switzerland and Germany, MediCrops is not only a supplier but also an active developer of new healthcare solutions, aiming to reshape patient care through technology. The company leverages a network of medical professionals specializing in cannabis-based treatments to provide patients with direct access to personalized therapies via digital platforms. MediCrops has expanded its infrastructure by acquiring its own pharmacy and medical practice, further integrating its services and enhancing its capacity to deliver tailored healthcare solutions. The company is committed to revolutionizing access to new treatment methods and continuously expanding its presence in the digital health sector.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Freienbach, Switzerland
Employees: 12
Open positions: None listed
Dealroom signal: 51.7/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Patient Care, Telemedicine, Cannabis, Biotech and Pharma, Medicinal Cannabis, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 3 companies, latest Jan 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Aug 2022	$3.4M	$92M	Undisclosed	↗
LATE VC✓Equity / VC	Jan 2021	$18M	$73M	Undisclosed	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

MediCrops website traffic

Latest recorded traffic for MediCrops is 460 monthly website visits, down 72.9% over the last three months. MediCrops's team grew 9.1% over the past year.

Latest monthly visits460 3-month web change-72.9% 1-year team growth+9.1%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EPEurox PharmaA company developing and manufacturing cannabis based medicines	Nideggen, Germany	Operational	—	$19M	$110M
CACanaxCannabis extraction company for the development of CBD-based products for pharmaceutical and cosmectuical industry	Milan, Italy	Operational
POPortocannaMedical cannabis processor creating Europe's largest symbiotic ecosystem with GMP facilities and diverse distribution	Santarém, Portugal	Operational
SGSemdor Pharma GroupSpecializing in narcotics and medical cannabis, working with wholesalers, suppliers, and pharmacies	Cologne, Germany	Operational
MEMEDICANNXMedicannX specializes in growing high-quality medical cannabis in Israel using advanced aeroponic cultivation techniques	Tirat Karmel, Israel	Operational
TOTikun OlamTikun Olam Ltd breeds proprietary cannabis strains and develops standardized products with accurate dosage	Tel Aviv-Yafo, Israel	Operational
ECElevate CBDManufacturing high-quality CBD products in the U.S. for both humans and pets	Telford, United States	Operational
SMSyqe MedicalSyqe Medical aims to transform cannabis and other psychoactive botanicals into mainstream medical drugs	Tel Aviv-Yafo, Israel	Acquired